LYMDEVRA Trademark

Trademark Overview

On Tuesday, October 21, 2025, a trademark application was filed for LYMDEVRA with the United States Patent and Trademark Office. The USPTO has given the LYMDEVRA trademark a serial number of 99454183. The federal status of this trademark filing is PUBLISHED FOR OPPOSITION as of Tuesday, April 14, 2026. This trademark is owned by Sarepta Therapeutics, Inc.. The LYMDEVRA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Biological preparations for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Pharmaceutical preparations containing viral vectors for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Pharmaceutical preparations based on morpholino oligomer technology platform for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders, and for the regulation of protein production; Pharmaceutical preparations that modulate RNA expression for the treatment of neuromuscular diseases and disorders, muscular dystrop...
lymdevra

General Information

Serial Number99454183
Word MarkLYMDEVRA
Filing DateTuesday, October 21, 2025
Status686 - PUBLISHED FOR OPPOSITION
Status DateTuesday, April 14, 2026
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, April 14, 2026

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Biological preparations for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Pharmaceutical preparations containing viral vectors for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Pharmaceutical preparations based on morpholino oligomer technology platform for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders, and for the regulation of protein production; Pharmaceutical preparations that modulate RNA expression for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders, and for the regulation of protein production; Gene therapy products, namely, gene delivery pharmaceuticals for treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Pharmaceutical preparations for gene therapy, gene editing, and genome editing for treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Gene therapies, in the nature of pharmaceutical preparations, for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Pharmaceutical preparations, biological preparations and gene therapy products in the nature of pharmaceutical and biological preparations for the treatment of genetic disorders and diseases

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, October 21, 2025
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameSarepta Therapeutics, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressCambridge, MA 02142
US
Party NameSarepta Therapeutics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressCambridge, MA 02142
US

Trademark Events

Event DateEvent Description
Tuesday, October 21, 2025NEW APPLICATION ENTERED
Tuesday, October 21, 2025NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, October 21, 2025APPLICATION FILING RECEIPT MAILED
Saturday, March 7, 2026ASSIGNED TO EXAMINER
Friday, March 20, 2026APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, April 8, 2026NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, April 14, 2026PUBLISHED FOR OPPOSITION
Tuesday, April 14, 2026OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

Related Keywords

lymdevra disorders diseases muscular treatment preparations neuromuscular genetic pharmaceutical system nervous